IDEXX Laboratories IDXX · NASDAQ
$560.36 +2.41% (+$13.18)
Summary
77 / 100 · Bulios Score
What speaks for it
- Out of every 100 USD of revenue, 25 USD is left as net profit.
- It earns 41 USD a year on every 100 USD of invested capital.
- Earnings per share grew by 18% a year over the last 3 years.
What to watch
- The share price is above the Bulios Fair Price.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 37.8 USD for 1 USD of yearly profit. Over the last five years it was 54.6 USD on average.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 9.7% a year over 5 years. Over the last 3 years it grew by 8.5% a year. For the next fiscal year analysts expect revenue to grow by 9.7%. Earnings per share grew by 18% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 38 USD
- Research and development 5.7 USD
- Sales and administration 25 USD
- Taxes and other 7.0 USD
- Net profit 25 USD
Net profit, industry median (Medical - Diagnostics & Research) 8.8 USD
Out of every 100 USD of revenue, 25 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 13
- Hold 9
- Sell 1
Today's price within the analysts' price targets
The average target of $665 is 19% above today's price. 57% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Product 59%
- Service 41%
By region
- UNITED STATES 61%
- EMEA 21%
- Asia Pacific 7.9%
- Europe, the Middle East, and Africa, Other 5.1%
- CANADA 3.7%
- Other 2.0%
Product brings in 59% of revenue.
Segments in detail